Beijing Youan Hospital, Capital Medical University
首都医科大学附属北京佑安医院
Listed for 7 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.
Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.
No official website checked for this hospital yet.
Research at Beijing Youan Hospital, Capital Medical University
Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.
Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed
- Hepatocellular carcinoma肝细胞癌67 papers led
- Osteosarcoma骨肉瘤1 paper led
- Haemophagocytic lymphohistiocytosis噬血细胞性淋巴组织细胞增生症2 papers led
- Wilson disease肝豆状核变性(Wilson 病)5 papers led
- Hepatic echinococcosis肝包虫病0 papers led
- Primary biliary cholangitis原发性胆汁性胆管炎7 papers led
- Primary sclerosing cholangitis原发性硬化性胆管炎0 papers led
Not listed for: Nasopharyngeal carcinoma, Oesophageal squamous cell carcinoma, Stomach cancer, Hepatoblastoma, Retinoblastoma, Chordoma, Gastrointestinal stromal tumour, Neuroblastoma, Ewing sarcoma, Multiple myeloma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Biliary atresia, Anti-NMDA receptor encephalitis, Takayasu arteritis, Idiopathic pulmonary fibrosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Behçet disease, Alport syndrome, IgA nephropathy, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.
Cancer
Hepatocellular carcinoma
肝细胞癌Led 67 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.4%.
- Open trials led
- 0
- recruiting or about to
17 hospitals in Beijing for hepatocellular carcinoma194 hospitals in China for hepatocellular carcinoma
Open trials with this hospital 4
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingMRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)
- Phase
- Phase 1/Phase 2
- Started
- 2026-04
- Registry
- NCT07479485
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Fuzhou, Nanjing, Tianjin, Zhengzhou
- RecruitingComputer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion
- Phase
- Not given
- Started
- 2025-09
- Registry
- NCT07170345
Age 18 years to 18 years (registered criteria)
Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Guangzhou, Nanning, Shanghai, Shenyang, Wenzhou, Zhengzhou, Zhuhai
- RecruitingNWRD06 DNA Plasmid for HCC After Curative Resection.
- Phase
- Phase 2
- Started
- 2025-12
- Registry
- NCT07324304
Age 18 years to 65 years (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Hangzhou, Harbin
- RecruitingAnlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
- Phase
- Phase 3
- Started
- 2023-05
- Registry
- NCT05862337
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 46 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Lanzhou, Luzhou, Nanchang, Nanchong, Nanning, Nantong, Ningbo, Shanghai, Shenyang, Taizhou, Tianjin, Urumqi, Wenzhou, Xi'an, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led67
- Contrast-enhanced MRI for identifying the steatohepatitic hepatocellular carcinoma from small hepatocellular carcinoma.
- Machine Learning-Based Model for Predicting Recurrence-Free Survival After Interventional Therapy in Malnourished Hepatocellular Carcinoma Patients.
- Changes in systemic immune-inflammation index (SII) predict the prognosis of patients with hepatitis B-related hepatocellular carcinoma treated with lenvatinib plus PD-1 inhibitors.
- Emerging roles of cuproptosis in liver diseases.
- Integrating single-cell RNA sequencing with spatial transcriptomics reveal the fibrosis-related genes in hepatocellular carcinoma.
- A prediction model based on machine learning: prognosis of HBV-induced HCC male patients with smoking and drinking habits after local ablation treatment.
- The relationship between systemic therapies and low skeletal muscle mass in patients with intermediate and advanced hepatocellular carcinoma.
- The Roles and Clinical Significance of Major Hepatic-Derived Metabolites in Hepatocellular Carcinoma.
- Oral Chinese patent medicine combined with transarterial chemoembolization for the treatment of unresectable hepatocellular carcinoma: A Bayesian network meta-analysis.
- Immune Escape-Related Gene NXT1 as a Potential Prognostic and Therapeutic Target in Hepatocellular Carcinoma.
- The methylation signature of hepatocellular carcinoma trajectory based on pseudotime and chronological time for predicting precancerous patients.
- Predictive Value of Preoperative Serum Substance P Levels for Post-Transplant Recurrence in Patients With Hepatocellular Carcinoma.
- A Novel Nomogram for Predicting Recurrence of Hepatocellular Carcinoma After Liver Transplantation.
- Reduced muscle mass is an important part of Global Leadership Initiative on Malnutrition criteria in nutritional diagnosis of hepatocellular carcinoma.
- Immunotherapy for hepatocellular carcinoma.
- A Systematic Review and Meta-Analysis of MRI Radiomics for Predicting Microvascular Invasion in Patients with Hepatocellular Carcinoma.
- Therapeutic analysis of 632 cases treated by transcatheter arterial chemoembolization combined with ablation in hepatocellular carcinoma: A retrospective study.
- Prognostic model for predicting recurrence in hepatocellular carcinoma patients with high systemic immune-inflammation index based on machine learning in a multicenter study.
- Machine learning-based model for predicting tumor recurrence after interventional therapy in HBV-related hepatocellular carcinoma patients with low preoperative platelet-albumin-bilirubin score.
- Nomogram for predicting post-therapy recurrence in BCLC A/B hepatocellular carcinoma with Child-Pugh B cirrhosis.
- Construction and validation of a machine learning-based nomogram to predict the prognosis of HBV associated hepatocellular carcinoma patients with high levels of hepatitis B surface antigen in primary local treatment: a multicenter study.
- Radiofrequency ablation plays double role in immunosuppression and activation of PBMCs in recurrent hepatocellular carcinoma.
- Hu-Qi-Zheng-Xiao Decoction Inhibits the Metastasis of Hepatocellular Carcinoma Cells by Suppressing the HIF-1α Signaling Pathway to Inhibit EMT, LCSC, and Angiogenic Process.
- HBx-induced upregulation of MAP1S drives hepatocellular carcinoma proliferation and migration via MAP1S/Smad/TGF-β1 loop.
- GALAD score as a prognostic model for recurrence of hepatocellular carcinoma after local ablation.
- Diagnostic value of serum STIP1 in HCC and AFP-negative HCC.
- Relationship between STAP1 methylation in peripheral blood T cells and the clinicopathological characteristics and prognosis of patients within 5-cm diameter HCC.
- Efficacy of CalliSpheres® drug-loaded microspheres combined with doxorubicin in hepatocellular carcinoma.
- Unraveling the Heterogeneity of Tumor Immune Microenvironment in Hepatocellular Carcinoma by SingleCell RNA Sequencing and its Implications for Prognosis and Therapeutic Response.
- Dynamic changes of phenotype and function of natural killer cells in peripheral blood before and after thermal ablation of hepatitis B associated hepatocellular carcinoma and their correlation with tumor recurrence.
- Diagnosis of primary clear cell carcinoma of the liver based on Faster region-based convolutional neural network.
- CT radiomics for prediction of microvascular invasion in hepatocellular carcinoma: A systematic review and meta-analysis.
- Reprogramming of lipid metabolism in hepatocellular carcinoma resulting in downregulation of phosphatidylcholines used as potential markers for diagnosis and prediction.
- Impact of Traditional Chinese Medicine on Prognosis of Patients with Hepatocellular Carcinoma: A Retrospective Cohort Study.
- Individual surveillance by competing risk model for patients with hepatocellular carcinoma occurrence in all-cause cirrhosis.
- CHB patients with rtA181T-mutated HBV infection are associated with higher risk hepatocellular carcinoma due to increases in mutation rates of tumour suppressor genes.
- Comparison of acknowledged hepatocellular carcinoma risk scores in high-risk hepatitis C patients with sustained virological response.
- The Advancement of Nanomaterials for the Detection of Hepatitis B Virus and Hepatitis C Virus.
- mRNA sequencing and CyTOF analysis revealed ASPP2 altered the response patterns of hepatocellular carcinoma HepG2 cells to usnic acid.
- Dynamic Changes of Cytokine Profiles and Their Correlation With Tumor Recurrence Following Thermal Ablation in Hepatocellular Carcinoma.
- The monocyte to lymphocyte ratio not only at baseline but also at relapse predicts poor outcomes in patients with hepatocellular carcinoma receiving locoregional therapy.
- ASPP2 reduction attenuates HBV induced chronic liver damage: A hybrid mouse model study.
- Knockout of ASPP2 promotes DEN-induced hepatocarcinogenesis via the NF-κB pathway in mice.
- Inactivation of tumor suppressor TAp63 by hepatitis B virus X protein in hepatocellular carcinoma.
- Digital Droplet PCR for Detection and Quantitation of Hepatitis Delta Virus.
- mTORi-based immunosuppression reduces HCC recurrence at the expense of increased adverse side effects: A systematic review and meta-analysis.
- Epidemic, risk factors of carbapenem-resistant Klebsiella pneumoniae infection and its effect on the early prognosis of liver transplantation.
- Diagnostic and prognostic value of STAP1 and AHNAK methylation in peripheral blood immune cells for HBV-related hepatopathy.
- Variations in dynamic tumor-associated antigen-specific T cell responses correlate with HCC recurrence after thermal ablation.
- Nomogram established on account of Lasso-Cox regression for predicting recurrence in patients with early-stage hepatocellular carcinoma.
- m7G regulator-mediated methylation modification patterns define immune cell infiltration and patient survival.
- Study on the Retreatment, Outcome, and Potential Predictors of Recurrence in Patients With Recurrence of Hepatitis B After Functional Cure.
- Comprehensive Analysis of Epigenetic Associated Genes on Differential Gene Expression and Prognosis in Hepatocellular Carcinoma.
- AHNAK Contributes to Hepatocellular Carcinoma Growth by Interacting with IGF-1R.
- Gender differences in demographic and clinical characteristics in patients with HBV-related liver diseases in China.
- Distinct tumour antigen-specific T-cell immune response profiles at different hepatocellular carcinoma stages.
- Association of HSD17B13 rs72613567: TA allelic variant with liver disease: review and meta-analysis.
- Interferon-Induced Transmembrane Protein 3 Expression Upregulation Is Involved in Progression of Hepatocellular Carcinoma.
- Crosstalk between hepatic stellate cells and tumor cells in the development of hepatocellular carcinoma.
- Progression on the Roles and Mechanisms of Tumor-Infiltrating T Lymphocytes in Patients With Hepatocellular Carcinoma.
- Evaluation of clinical outcomes of radiofrequency ablation and surgical resection for hepatocellular carcinoma conforming to the Milan criteria: A systematic review and meta-analysis of recent randomized controlled trials.
- Dysbiosis of Gut Microbiota Promotes Hepatocellular Carcinoma Progression by Regulating the Immune Response.
- Durability of hepatitis B surface antigen seroclearance and subsequent risk for hepatocellular carcinoma: A meta-analysis.
- Exploring new targets for the treatment of hepatitis-B virus and hepatitis-B virus-associated hepatocellular carcinoma: A new perspective in bioinformatics.
- Magnetic resonance radiomics signatures for predicting poorly differentiated hepatocellular carcinoma: A SQUIRE-compliant study.
- Intracellular alpha-fetoprotein interferes with all-trans retinoic acid induced ATG7 expression and autophagy in hepatocellular carcinoma cells.
- Adoptive Transfer of Autologous Invariant Natural Killer T Cells as Immunotherapy for Advanced Hepatocellular Carcinoma: A Phase I Clinical Trial.
Chinese-language papers (not in the count)10
- [Research advances in occurrence risk assessment and early-stage diagnosis of hepatocellular carcinoma].
- [Factors affecting tumorigenicity in liver cancer xenografts].
- [Advances in serological non-invasive diagnosis for metabolic dysfunction-associated fatty liver disease].
- [Exploration of cystathionine β-synthase and cystathionine γ-lyase gene expression poor prognostic predictive value with the application of bioinformatics data mining in liver cancer].
- [The role of circulating tumor DNA in the diagnosis and prognosis of hepatocellular carcinoma].
- [The study of a key molecule Caspase-1 of inflammasome in hepatitis B virus-related diseases].
- [Recommendations of EASL clinical practice guidelines on haemochromatosis].
- [Research progress in radiomics based on CT and MRI images for prediction of microvascular invasion in hepatocellular carcinoma].
- [Sorafenib regulates vascular endothelial growth factor by runt-related transcription factor-3 to inhibit angiogenesis in hepatocellular carcinoma].
- [Study of the risk factors for recurrence of early and late stage hepatocellular carcinoma after hepatic artery embolization combined with radiofrequency ablation therapy].
All its trials on ClinicalTrials.gov, any status19
- Adoptive Autologous iNKT Cells for the Treatment of Progressed Hepatocellular Carcinoma Continuing on PD-1 Inhibitor Therapy
- Study of Adoptive Transfer of iNKT Cells Combined With TAE/TACE to Treat Unresectable HCC
- Adoptive Transfer of Specific HCC Antigens CD8+ T Cells for Treating Patients With Relapsed/Advanced HCC
- Adoptive Transfer of iNKT Cells for Treating Patients With Relapsed/Advanced HCC
- MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)
- NWRD06 DNA Plasmid for HCC After Curative Resection.
- Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion
- Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
- A Phase 1b Study of GKL-006 Injection in Patients With Unresectable Hepatocellular Carcinoma
- A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies of Adult Chinese Participants With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC)
- Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GKL-006 Injection in Combination With TACE in Unresectable Hepatocellular Carcinoma
- A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma
- Detection Evaluation of a Novel Blood-based DNA Methylation Assay in Early-stage Hepatocellular Carcinoma Patients
- A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)
- YIV-906 (Formerly PHY906/KD018) With Sorafenib in HBV(+) Hepatocellular Carcinoma (HCC)
- A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma
- A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)
- Multicenter RCT of ADV-TK Gene Therapy Improving the Outcome of Liver Transplantation for Advanced HCC
- Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC)
Cancer
Osteosarcoma
骨肉瘤Led 1 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.04%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
37 hospitals in Beijing for osteosarcoma570 hospitals in China for osteosarcoma
No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
Blood disorders
Haemophagocytic lymphohistiocytosis
噬血细胞性淋巴组织细胞增生症Led 2 of the 399 English-language PubMed papers on haemophagocytic lymphohistiocytosis with an author in mainland China, 2021–2025: 0.5%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
11 hospitals in Beijing for haemophagocytic lymphohistiocytosis66 hospitals in China for haemophagocytic lymphohistiocytosis
No open trial on haemophagocytic lymphohistiocytosis lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Other diseases
Wilson disease
肝豆状核变性(Wilson 病)Led 5 of the 201 English-language PubMed papers on Wilson disease with an author in mainland China, 2021–2025: 2.5%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
3 hospitals in Beijing for Wilson disease28 hospitals in China for Wilson disease
Open trials with this hospital 2
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingTrientine Tetrahydrochloride Administered Once a Day for the First Line Treatment of Wilson's Disease Patients.
- Phase
- Phase 3
- Started
- 2026-09
- Registry
- NCT07465718
Age 8 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Hangzhou
- RecruitingChina Registry for Genetic / Metabolic Liver Diseases
- Phase
- Not given
- Started
- 2015-06
- Registry
- NCT03131427
Age not stated (registered criteria)
Led by Beijing Friendship Hospital; 1 listed hospital as study siteBeijing
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led5
- Emerging roles of cuproptosis in liver diseases.
- Uncovering the Critical Role of Cuproptosis in Wilson Disease: Insights Into Potential Therapeutic Targets.
- The potential serum sphingolipid biomarkers for distinguishing Wilson disease.
- Wilson disease in pregnancy: A case series.
- Stem Cells Treatment for Wilson Disease.
Chinese-language papers (not in the count)9
- [Recommendations from the European Association for the Study of the Liver and the European Reference Network for Rare Liver Diseases Clinical Practice Guidelines for hepatolenticular degeneration].
- [Progress on the research of hepatolenticular degeneration].
- [Inherited metabolic liver disease causing copper deposition].
- [Research progress of inherited metabolic liver disease in 2024].
- [Application of zinc agents in Wilson's disease].
- [An introduction to multidisciplinary recommendations for Wilson's disease comprehensive diagnosis and management: 2022 practice guidance from the American Association for the Study of Liver Diseases].
- [Interpretation of the 2022 edition guidelines for hepatolenticular degeneration diagnosis and treatment].
- [Management of hepatolenticular degeneration during pregnancy].
- [Research progress in gene therapy for Wilson's disease].
All its trials on ClinicalTrials.gov, any status2
Other diseases
Hepatic echinococcosis
肝包虫病Led no English-language PubMed papers on hepatic echinococcosis in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
6 hospitals in Beijing for hepatic echinococcosis44 hospitals in China for hepatic echinococcosis
No open trial on hepatic echinococcosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
Primary biliary cholangitis
原发性胆汁性胆管炎Led 7 of the 300 English-language PubMed papers on primary biliary cholangitis with an author in mainland China, 2021–2025: 2.3%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
15 hospitals in Beijing for primary biliary cholangitis153 hospitals in China for primary biliary cholangitis
Open trials with this hospital 2
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA
- Phase
- Phase 3
- Started
- 2025-12
- Registry
- NCT07282353
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesBaoji, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Hangzhou, Harbin, Hefei, Linyi, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shenzhen, Shiyan, Taizhou, Tianjin, Xi'an, Xiamen, Zhanjiang, Zhengzhou
- RecruitingSeladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
- Phase
- Phase 3
- Started
- 2023-09
- Registry
- NCT06051617
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Hefei, Shanghai, Urumqi, Wuhan, Xi'an, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led7
- Non-invasive assessment of esophageal and fundic varices in patients with primary biliary cholangitis.
- Clinical outcomes and early- prognostic biomarkers of primary biliary cholangitis with ductopenia.
- A new method to estimate the histological stage of primary biliary cholangitis.
- Ultrasound imaging findings in primary biliary cholangitis.
- Prevalence and prognostic significance of main metabolic risk factors in primary biliary cholangitis: a retrospective cohort study of 789 patients.
- Using two-step cluster analysis to classify inpatients with primary biliary cholangitis based on autoantibodies: A real-world retrospective study of 537 patients in China.
- Disease predisposition of human leukocyte antigen class II genes influences the gut microbiota composition in patients with primary biliary cholangitis.
Chinese-language papers (not in the count)1
Earlier papers (2016–2020)5
- Early Prognostic Utility of Gp210 Antibody-Positive Rate in Primary Biliary Cholangitis: A Meta-Analysis.
- [An analysis of the serological characteristics of anti-mitochondrial M2 subtype in patients with drug-induced liver injury and primary biliary cholangitis].
- Clonal characteristics of paired infiltrating and circulating B lymphocyte repertoire in patients with primary biliary cholangitis.
- [How to understand the clinical significance of autoantibodies in primary biliary cholangitis].
- Clonal Characteristics of Circulating B Lymphocyte Repertoire in Primary Biliary Cholangitis.
All its trials on ClinicalTrials.gov, any status5
- A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA
- Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
- CS0159 in Chinese Patients With PBC (Primary Biliary Cholangitis)
- A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis
- Safety and Efficacy of Tauroursodeoxycholic Acid Versus Ursofalk in the Treatment of Adult Primary Biliary Cirrhosis
Other diseases
Primary sclerosing cholangitis
原发性硬化性胆管炎Led no English-language PubMed papers on primary sclerosing cholangitis in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
10 hospitals in Beijing for primary sclerosing cholangitis89 hospitals in China for primary sclerosing cholangitis
No open trial on primary sclerosing cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Chinese-language papers (not in the count)1
All its trials on ClinicalTrials.gov, any status1
Getting in touch
Name card to show staff or a driver
首都医科大学附属北京佑安医院
Beijing Youan Hospital, Capital Medical University
北京
Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.
Inquiry letter in English and Chinese
Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.
Records hospitals usually ask for
- A recent summary or letter from the treating doctor
- Pathology report
- Scans (CT, MRI, PET) with their reports, and the images if possible
- Treatments so far, with dates
- Current medicines
What to do next
Where these numbers come from
Papers
English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions
Trials
ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.
Identifiers and other names
ROR
Beijing Youan Hospital; Beijing You An Hospital; Capital Medical University affiliated Beijing You An Hospital; Beijing You An Hospital Affiliated to the Capital Medical University; Capital Medical University Affiliated Beijing Youan Hospital; Beijing YouAn Hospital Capital Medical University; Beijing Youan Hospital Affiliated with Capital Medical University; Beijing Youan Hospital of Capital Medical University